XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Stock Based Compensation for Employees and Non Employees

Under each of the legal entity’s equity plans, we recorded stock-based compensation in the following expense categories in our condensed consolidated statements of operations for employees and non-employees:

 

 

 

Three Months Ended September 30, 2021

 

 

Nine Months Ended September 30, 2021

 

 

 

BridgeBio
Equity Plan

 

 

Other
Subsidiaries
Equity Plan

 

 

Total

 

 

BridgeBio
Equity Plan

 

 

Other
Subsidiaries
Equity Plan

 

 

Total

 

 

 

(in thousands)

 

Research and development

 

$

4,198

 

 

$

610

 

 

$

4,808

 

 

$

44,661

 

 

$

1,880

 

 

$

46,541

 

Selling, general and administrative

 

 

11,292

 

 

 

30

 

 

 

11,322

 

 

 

33,555

 

 

 

2,965

 

 

 

36,520

 

Total stock-based compensation

 

$

15,490

 

 

$

640

 

 

$

16,130

 

 

$

78,216

 

 

$

4,845

 

 

$

83,061

 

 

 

 

Three Months Ended September 30, 2020

 

 

Nine Months Ended September 30, 2020

 

 

 

 

BridgeBio
Equity Plan

 

 

Eidos
Equity Plan

 

 

Other
Subsidiaries
Equity Plan

 

 

Total

 

 

BridgeBio
Equity Plan

 

 

Eidos
Equity Plan

 

 

Other
Subsidiaries
Equity Plan

 

 

Total

 

 

 

 

(in thousands)

 

 

Research and development

 

$

4,974

 

 

$

1,648

 

 

$

310

 

 

$

6,932

 

 

$

13,194

 

 

$

4,011

 

 

$

538

 

 

$

17,743

 

 

General and administrative

 

 

8,895

 

 

 

1,792

 

 

 

80

 

 

 

10,767

 

 

 

24,260

 

 

 

4,074

 

 

 

236

 

 

 

28,570

 

 

Total stock-based compensation

 

$

13,869

 

 

$

3,440

 

 

$

390

 

 

$

17,699

 

 

$

37,454

 

 

$

8,085

 

 

$

774

 

 

$

46,313

 

 

Summary of Stock Option Activity

The following table summarizes BridgeBio’s stock option activity under the Plans for the nine months ended September 30, 2021:

 

 

Options
Outstanding

 

 

Weighted-
Average
Exercise
Price per
Option

 

 

Weighted-
Average
Remaining
Contractual
Life (years)

 

 

Aggregate
Intrinsic
Value
(in thousands)

 

Outstanding as of December 31, 2020

 

 

 

 

7,632,961

 

 

 

 

 

 

 

 

 

 

Regular equity program

 

6,778,112

 

 

 

 

 

$

23.83

 

 

 

8.8

 

 

 

320,473

 

Exchange Program

 

854,849

 

 

 

 

 

$

2.22

 

 

 

8.2

 

 

 

58,891

 

Granted

 

 

 

 

3,830,863

 

 

 

 

 

 

 

 

 

 

Regular equity program

 

1,054,191

 

 

 

 

 

$

63.82

 

 

 

 

 

 

 

Eidos Awards Exchange

 

2,776,672

 

 

 

 

 

$

16.33

 

 

 

 

 

 

 

Exercised

 

 

 

 

(1,069,978

)

 

 

 

 

 

 

 

 

 

Regular equity program

 

(292,143

)

 

 

 

 

$

19.93

 

 

 

 

 

 

 

Eidos Awards Exchange

 

(497,082

)

 

 

 

 

$

16.10

 

 

 

 

 

 

 

Exchange Program

 

(280,753

)

 

 

 

 

$

1.68

 

 

 

 

 

 

 

Cancelled

 

 

 

 

(222,579

)

 

 

 

 

 

 

 

 

 

Regular equity program

 

(105,089

)

 

 

 

 

$

27.41

 

 

 

 

 

 

 

Eidos Awards Exchange

 

(113,320

)

 

 

 

 

$

20.17

 

 

 

 

 

 

 

Exchange Program

 

(4,170

)

 

 

 

 

$

3.09

 

 

 

 

 

 

 

Outstanding as of September 30, 2021

 

 

 

 

10,171,267

 

 

 

 

 

 

 

 

 

 

Regular equity program

 

7,435,071

 

 

 

 

 

$

29.60

 

 

 

8.3

 

 

$

146,291

 

Eidos Awards Exchange

 

2,166,270

 

 

 

 

 

$

16.18

 

 

 

7.1

 

 

$

66,554

 

Exchange Program

 

569,926

 

 

 

 

 

$

2.48

 

 

 

7.4

 

 

$

25,299

 

Exercisable as of September 30, 2021

 

 

 

 

4,486,617

 

 

 

 

 

 

 

 

 

 

Regular equity program

 

2,889,270

 

 

 

 

 

$

23.73

 

 

 

8.0

 

 

$

68,522

 

Eidos Awards Exchange

 

1,102,497

 

 

 

 

 

$

12.22

 

 

 

6.2

 

 

$

38,200

 

Exchange Program

 

494,850

 

 

 

 

 

$

2.03

 

 

 

7.4

 

 

$

22,190

 

Summary of Restricted Stock Units Activity

The following table summarizes BridgeBio’s RSU activity under the Plans for the nine months ended September 30, 2021:

 

 

 

Unvested
Shares of
RSUs
Outstanding

 

 

Weighted-
Average
Grant Date
Fair Value

 

Balance as of December 31, 2020

 

 

1,053,838

 

 

$

34.21

 

Granted

 

 

1,148,597

 

 

$

65.25

 

Vested

 

 

(377,499

)

 

$

44.01

 

Cancelled

 

 

(179,555

)

 

$

53.21

 

Balance as of September 30, 2021

 

 

1,645,381

 

 

$

51.55

 

Summary of Restricted Stock Award Activity

The following table summarizes our RSA activity under the Plans for the nine months ended September 30, 2021:

 

 

 

Unvested
Shares of
RSAs
Outstanding

 

 

Weighted-
Average
Grant Date
Fair Value

 

Balance as of December 31, 2020

 

 

3,364,366

 

 

$

4.47

 

Granted — Exchange Program

 

 

382,122

 

 

$

61.31

 

Vested — Exchange Program

 

 

(382,122

)

 

$

61.31

 

Vested — Regular equity program

 

 

(1,231,043

)

 

$

3.16

 

Cancelled — Regular equity program

 

 

(5,150

)

 

$

7.27

 

Balance as of September 30, 2021

 

 

2,128,173

 

 

$

5.22

 

2019 Employee Stock Purchase Plan  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Schedule of Assumptions Used to Determine Fair Value of Stock Option Granted

We used the Black-Scholes model to estimate the fair value of stock options and stock purchase rights under the ESPP. For the nine months ended September 30, 2021, we used the following weighted-average assumptions in the Black-Scholes calculations:

 

 

Nine Months Ended September 30, 2021

 

 

Stock Options

 

 

ESPP

 

Expected term (in years)

6.00-6.02

 

 

 

0.50

 

Expected volatility

51.43%-51.97%

 

 

47.61% - 52.04%

 

Risk-free interest rate

0.63%-1.09%

 

 

0.05% - 0.13%

 

Dividend yield

 

 

 

 

 

Weighted-average fair value of stock-based awards granted

$

31.03

 

 

$

16.29

 

Restricted Stock Awards  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Stock Based Compensation for Employees and Non Employees

During the three and nine months ended September 30, 2021, we recognized stock-based compensation expense related to RSAs under the Plans as follows:

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30, 2021

 

 

 

(in thousands)

 

Exchange Program

 

$

 

 

$

23,427

 

Other RSAs

 

 

1,486

 

 

 

4,754

 

Total stock-based compensation
   expense

 

$

1,486

 

 

$

28,181